Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057720 · ClinicalTrials.gov registry record · Phase 3
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
A Phase 3 study, sponsored by Telik.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT00057720 is a Phase 3 study that has completed, run by Telik. The registered enrollment target is 440 participants.
The verdict
NCT00057720, a Phase 3 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
Interventions
- DRUG TLK286 HCl for injection
- DRUG topotecan hydrochloride for injection
- DRUG doxorubicin HCl liposome injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2003-06 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057720
The ClinicalTrials.gov registry entry for NCT00057720 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TLK286 HCl for injection is the first listed.
NCT00057720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057720 about?
NCT00057720 is a clinical study titled "TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer". The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
What is the current status of trial NCT00057720?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2003-06. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00057720?
The interventions under investigation include: TLK286 HCl for injection (DRUG), topotecan hydrochloride for injection (DRUG), doxorubicin HCl liposome injection (DRUG).
Who is sponsoring clinical trial NCT00057720?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.